ivacaftor that it expects would provide intellectual property protection in the United States through its expiration date in 2027. The ocmany has a European patent that covers the composition-of-matter of ivacaftor that it expects would provide intellectual property protection in the European Union through its expiration date in 2025, subject to potential extension. The company has patents in the United States and European Union that cover the composition of matter of lumacaftor that it expects would provide intellectual property protection in these jurisdictions through their expiration dates in 2030 and 2026, respectively, subject to potential extension. VX-661 was granted orphan drug status in the United States and the European Union. The company has patents in the United States and European Union that covers the composition of matter of VX-661 that it expects would provide intellectual property protection in these jurisdictions through their expiration dates in 2027 and 2028, respectively, subject to potential extension. Regulations Products manufactured or distributed by the company pursuant to FDA approvals are subject to continuing regulation by the FDA. In addition to the statutes and regulations, the company is subject to regulation in the United States under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other federal, state, local and foreign statutes and regulations. History Vertex Pharmaceuticals Incorporated was founded in 1989. The company was incorporated in Massachusetts in 1989.
vertex pharmaceuticals inc
50 Northern Avenue
Boston, MA 02210
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for VRTX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.